New Cystic Fibrosis Study Findings Recently Were Reported by Researchers at Virginia Commonwealth University (A Review of Proton Pump Inhibitor Use In Cystic Fibrosis and Considerations for Deprescribing).

A recent report from researchers at Virginia Commonwealth University discusses the use of proton pump inhibitors (PPIs) in people with cystic fibrosis (pwCF). PPIs are commonly used to manage suspected GERD and pancreatic enzyme replacement therapy augmentation in pwCF, but limited data exist on their impact on key endpoints. The study suggests that the advent of CFTR modulator therapy may modify the need for PPI use and highlights the potential adverse outcomes associated with long-term PPI use in pwCF. The report aims to provide CF clinicians with guidance on deprescribing PPIs in their practice. [Extracted from the article]